Diabetes Mellitus: Gene Therapy

Andreea R Barbu, Uppsala University, Uppsala, Sweden
Nils Welsh, Uppsala University, Uppsala, Sweden

Published online: July 2007

DOI: 10.1002/9780470015902.a0005758.pub2

Full Article on Wiley Online Library

Gene therapy in diabetes mellitus can be defined as the transfer of deoxyribonucleic acid (DNA) to somatic cells to understand, treat or prevent the disease. For many gene therapy strategies in the treatment of diabetes, successful transduction of insulin-producing cells is a prerequisite. Therefore, much effort is currently directed in developing efficient and nontoxic vectors for gene transfer in pancreatic insulin-producing -cell. If available, these gene therapy tools could prevent the autoimmune -cell destruction in type 1 diabetes by protecting the remaining -cell mass in newly diagnosed diabetics or in prediabetic individuals at a high risk of becoming diabetic. Such an approach may also prove useful for promoting islet–graft survival after transplantation in diabetic patients. Alternatively, attempts are being made to genetically engineer cells to become artificial -cells. Such cells could conceivably compensate for the lost endogenous -cell mass and restore a regulated insulin secretion.

Keywords: diabetes; gene therapy; insulin; -cell; islet

References
	Agarwal RK, Kang Y, Zambidis E et al. (2000) Retroviral gene therapy with an immunoglobulin–antigen fusion construct protects from experimental autoimmune uveitis. Journal of Clinical Investigation 106: 245–252.
	Barbu AR, Bodin B, Welsh M, Jansson L and Welsh N (2006) A perfusion protocol for highly efficient transduction of intact pancreatic islets of Langerhans. Diabetologia 49(10): 2388–2391.
	Epstein AL, Marconi P, Argnani R and Manservigi R (2005) HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy. Current Gene Therapy 5(5): 445–458.
	Fathman CG, Costa GL and Seroogy CM (2000) Gene therapy for autoimmune disease. Clinical Immunology 95: S39–S43.
	Gainer AL, Suarez-Pinzon WL, Min WP et al. (1998) Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-Ig or soluble Fas ligand. Transplantation 66(2): 194–199.
	Goudy KS and Tish R (2005) Immunotherapy for the prevention and treatment of Type 1 diabetes. International Reviews of Immunology 24: 307–326.
	Kobinger GP, Deng S, Louboutin JP et al. (2004) Transduction of human islets with pseudotyped lentiviral vectors. Human Gene Therapy 15(2): 211–219.
	Lakey JR, Young AT, Pardue D et al. (2001) Nonviral transfection of intact pancreatic islets. Cell Transplantation 10(8): 697–708.
	Levine F and Labowitz G (1999) Towards gene therapy of diabetes mellitus. Molecular Medicine Today 5: 165–171.
	Mandrup-Poulsen T (1996) The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 39: 1005–1029.
	Mccabe C, Samali A and O’Brien T (2006) Cytoprotection of -cells: rational gene transfer strategies. Diabetes/Metabolism Research and Reviews 22: 241–252.
	Nir T and Dor Y (2005) How to make pancreatic -cells – prospects for cell therapy in diabetes. Current Opinion in Biotechnology 16: 524–529.
	Noguchi H and Matsumoto S (2006) Protein transduction technology offers a novel therapeutic approach for diabetes. Journal of Hepatobiliary Pancreatie Surgery 13(4): 306–313.
	Prud’homme GJ, Glinka Y, Khan AS and Dragia-Akli R (2006) Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Current Gene Therapy 6: 243–273.
	Rehman KK, Wang Z, Bottino R et al. (2005) Efficient gene delivery to human and rodent islets with double-stranded (ds) AAV-based vectors. Gene Therapy 12(17): 1313–1323.
	Samson SL and Chan L (2006) Gene therapy for diabetes: reinventing the islet. Trends in Endocrinology and Metabolism 17: 92–100.
	Sapir T, Shternhall K, Meivar-Levy I et al. (2005) Cell-replacement therapy for diabetes: Generating functional insulin-producing tissue from adult human liver cells. Proceedings of the National Academy of Sciences of the USA 102(22): 7964–7969.
	Serup P (2006) Embrionic stem cell-based diabetes therapy – a long road to travel. Diabetologia 49: 2537–2540.
Further Reading
	Ferber S, Halkin A, Cohen H et al. (2000) Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nature Medicine 6: 568–572.
	Harlan DM (2004) Gene-altered islets for transplant: giant leap or small step? Endocrinology 145(2): 463–466.
	Kaneto H, Nakatani Y, Miyatsuka T et al. (2005) PDX-1/VP16 fusion protein, together with NeuroD or Ngn3, markedly induces insulin gene transcription and ameliorates glucose tolerance. Diabetes 54(4): 1009–1022.
	Rane SH and Reddy EP (2000) Cell cycle control of pancreatic -cell proliferation. Frontiers in Bioscience 5: d1–d19.
	Soria B, Roche E, Berná G et al. (2000) Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes 49: 157–162.
	Trucco M (2005) Regeneration of the pancreatic -cell. Journal of Clinical Investigation 115(1): 5–12.
	Tsokos GC and Nepom GT (2000) Gene therapy in the treatment of autoimmune diseases. Journal of Clinical Investigation 106: 181–183.
	Welsh N (1999) Gene therapy in diabetes mellitus: promises and pitfalls. Current Opinions in Molecular Therapy 1: 464–470.
	Wildbaum G, Westermann J, Maor G and Karin N (2000) A targeted DNA vaccine encoding Fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis. Journal of Clinical Investigation 106: 671–679.
	Yechoor V and Chan L (2005) Gene therapy progress and prospects: gene therapy for diabetes mellitus. Gene Therapy 12(2): 101–107.

Article Title:	Diabetes Mellitus: Gene Therapy
* Name:
* E-mail:
* Note:

Diabetes Mellitus: Gene Therapy

Related Sub-Topics: